George R. Stark

George R. Stark

Auto-generated profile, based on publicly available information

George R. Stark

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Immunity
Verified
Journal Article
Closed access
GSGeorge R. Stark
George R. Stark
JDJames E. Darnell
James E. Darnell

17 May 2007 in Genes & Development
Verified
Journal Article
Closed access
PDF file
JYJinbo Yang
Jinbo Yang
XLXudong Liao
Xudong Liao
MAMukesh K. Agarwal
Mukesh K. Agarwal
LBLaura Barnes
Laura Barnes
PAPhilip E. Auron
Philip E. Auron
GSGeorge R. Stark
George R. Stark
Gp130-linked cytokines such as interleukin-6 (IL-6) stimulate the formation of tyrosine-phosphorylated signal transducer and activator of transcription 3 (P-STAT3), which activates many genes, including the STAT3 gene itself. The resulting increase in the concentration of unphosphorylated STAT3 (U-STAT3) drives a second wave of expression of genes such asRANTES,IL6,IL8,MET, andMRASthat do not respond directly to P-STAT3. Thus, U-STAT3 sustains cytokine-dependent signaling at late times through a mechanism completely distinct from that used by P-STAT3. Many U-STAT3-responsive genes have κB elements that are activated by a novel transcription factor complex formed when U-STAT3 binds to unphosphorylated NFκB (U-NFκB), in competition with IκB. The U-STAT3/U-NFκB complex accumulates in the nucleus with help from the nuclear localization signal of STAT3, activating a subset of κB-dependent genes. Additional genes respond to U-STAT3 through an NFκB-independent mechanism. The role of signal-dependent increases in U-STAT3 expression in regulating gene expression is likely to be important in physiological responses to gp130-linked cytokines and growth factors that activate STAT3, and in cancers that have constitutively active P-STAT3.

1 February 2002 in Trends in Immunology
Verified
Journal Article
Closed access
CRChilakamarti Ramana
Chilakamarti Ramana
MGM.PIlar Gil
M.PIlar Gil
RSRobert D Schreiber
Robert D Schreiber
GSGeorge R Stark
George R Stark

24 September 2013 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
HCHyeonJoo Cheon
HyeonJoo Cheon
EHElise G Holvey‐Bates
Elise G Holvey‐Bates
JSJohn W Schoggins
John W Schoggins
SFSamuel Forster
Samuel Forster
PHPaul Hertzog
Paul Hertzog
GSGeorge R Stark
George R Stark
A single high dose of interferon‐β (IFNβ) activates powerful cellular responses, in which many anti‐viral, pro‐apoptotic, and anti‐proliferative proteins are highly expressed. Since some of these proteins are deleterious, cells downregulate this initial response rapidly. However, the expression of many anti‐viral proteins that do no harm is sustained, prolonging a substantial part of the initial anti‐viral response for days and also providing resistance to DNA damage. While the transcription factor ISGF3 (IRF9 and tyrosine‐phosphorylated STATs 1 and 2) drives the first rapid response phase, the related factor un‐phosphorylated ISGF3 (U‐ISGF3), formed by IFNβ‐induced high levels of IRF9 and STATs 1 and 2 without tyrosine phosphorylation, drives the second prolonged response. The U‐ISGF3‐induced anti‐viral genes that show prolonged expression are driven by distinct IFN stimulated response elements (ISREs). Continuous exposure of cells to a low level of IFNβ, often seen in cancers, leads to steady‐state increased expression of only the U‐ISGF3‐dependent proteins, with no sustained increase in other IFNβ‐induced proteins, and to constitutive resistance to DNA damage.

1 February 2005 in Cancer Research
Verified
Journal Article
Open access
PDF file
JYJinbo Yang
Jinbo Yang
MCMoitreyee Chatterjee-Kishore
Moitreyee Chatterjee-Kishore
SSSusan M. Staugaitis
Susan M. Staugaitis
HNHannah Nguyen
Hannah Nguyen
KSKarni Schlessinger
Karni Schlessinger
GSGeorge R. Stark
George R. Stark
Signal transducer and activator of transcription 3 (STAT3) is phosphorylated on tyrosine residue 705 in response to growth factors or cytokines to form activated homodimers that drive gene expression. Because the stat3 promoter has a binding site for STAT3 dimers, the amount of STAT3 protein increases when STAT3 is activated (e.g., in response to interleukin 6). Unphosphorylated STAT1 is known to drive the expression of certain genes. To explore the possibility of a similar role for the induced expression of unphosphorylated STAT3, we overexpressed either Y705F STAT3, which can not be phosphorylated on residue 705, or wild-type STAT3 in normal human mammary epithelial cells or STAT3-null mouse cells. The levels of many mRNAs were affected strongly by high levels of either form of STAT3. Some genes whose expression was increased by overexpressed STAT3, but not by activated STAT3 dimers, encode well-known oncoproteins (e.g., MRAS and MET). In many tumors, STAT3 is activated constitutively, and thus the unphosphorylated form is likely to be expressed highly, driving oncogene expression by a novel mechanism. In addition, expression of the stat3 gene is increased strongly in response to interleukin 6, and the high levels of unphosphorylated STAT3 that result drive a substantial late phase of gene expression in response to this cytokine. Thus, unphosphorylated STAT3, which activates gene expression by a novel mechanism distinct from that used by STAT3 dimers, is very likely to be an important transcription factor both in cancer and in responses to cytokines.

25 March 2008 in Cell Research
Verified
Journal Article
Closed access
JYJinbo Yang
Jinbo Yang
GSGeorge R Stark
George R Stark